Advertisement

Picture [iito] No Tracking 650x80px
Organisation › Details

Relief Therapeutics (Group)

Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100™ (aviptadil), synthetic vasoactive intestinal peptide (VIP), is being investigated in two placebo-controlled U.S. Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. RLF-100™ is believed to be the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100™ under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19. Relief holds orphan drug designations from the U.S. FDA and the European Union for the use of RLF-100™ to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100™. RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. *

 

Period Start 2016-06-01 merged
Products Industry drug development
  Industry 2 aviptadil (NN)
Persons Person Selvaraju, Raghuram (Ram) (Relief Therapeutics 202010 Board Chairman)
  Person 2 Weinstein, Jack (Relief Therapeutics 202010– CFO before Avalon Group + Catalyst Pharmaceuticals + Sterlington Group)
     
Region Region Genève (Geneva) GE
  Country Switzerland
  Street 15 Avenue de Sécheron
Fondation EIP, Bâtiment F2/F3
  City 1202 Genève GE
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Relief Therapeutics Holding AG. (10/8/20). "Press Release: Relief Therapeutics Appoints Industry Veteran, Jack Weinstein, as Chief Financial Officer and Treasurer". Geneva.
     
   
Record changed: 2020-10-09

Advertisement

Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Relief Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81




» top